Caribou Biosciences, Inc. cash flow to debt ratio of -407.65% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Caribou Biosciences, Inc.'s free cash flow has increased -22.36% from $-144.71M last year to $-112.35M, signaling increasing performance

Caribou Biosciences, Inc.'s debt to equity ratio is 0.26, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Caribou Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.10 last year to 0.26 today, signaling weakened financials

Caribou Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Caribou Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Caribou Biosciences, Inc.'s profit margin has increased (-20.30%) in the last year from -1.49K% to -1.19K%, signaling increasing performance

Caribou Biosciences, Inc.'s short-term assets of $145.23M exceed its short-term liabilities of $25.41M

Caribou Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Caribou Biosciences, Inc.'s return on equity of -100.13%, is lower than 15.00%, indicating bad performance

Caribou Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Caribou Biosciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Caribou Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Caribou Biosciences, Inc. has negative free cash flow, indicating cash burn

Caribou Biosciences, Inc.'s yearly earnings has increased -0.66% since last year from $-149.10M to $-148.12M, signaling increasing performance

Caribou Biosciences, Inc.'s yearly revenue has increased 11.66% since last year from $9.99M to $11.16M, signaling increasing performance

ROIC -100.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Caribou Biosciences, Inc.'s 3-year revenue CAGR of -6.95% is negative, indicating declining revenue over the past 3 years

Caribou Biosciences, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Caribou Biosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Caribou Biosciences, Inc. has insufficient data to evaluate this check.

Caribou Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Caribou Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Caribou Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Caribou Biosciences, Inc. is overvalued relative to its fair value price of -6.16 based on Earnings Fair Value model

Caribou Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Caribou Biosciences, Inc. has a price-to-book ratio of 1.64x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Caribou Biosciences, Inc. has a price-to-sales ratio of 14.97x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue